» Articles » PMID: 20798514

RRM2 Computational Phosphoprotein Network Construction and Analysis Between No-tumor Hepatitis/cirrhotic Liver Tissues and Human Hepatocellular Carcinoma (HCC)

Overview
Date 2010 Aug 28
PMID 20798514
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

RRM2 computational phosphoprotein network construction and analysis of human hepatocellular carcinoma (HCC) is very useful to identify novel markers and potential targets for prognosis and therapy. By integration of gene regulatory network infer (GRNInfer) and the database for annotation, visualization and integrated discovery (DAVID) we identified and constructed significant molecule RRM2 phosphoprotein network from 25 no-tumor hepatitis/cirrhotic liver tissues and 25 HCC patients in the same GEO Dataset GSE10140-10141. We gained the negative result of RRM2 phosphoprotein module through the net numbers of activation minus inhibition compared with no-tumor hepatitis/cirrhotic liver tissues and predicted possibly the decrease of RRM2 phosphoprotein module in HCC. Our integrative result showed that RRM2 phosphoprotein cluster of HCC contained both in human no-tumor hepatitis/cirrhotic liver tissues and HCC terms of phosphoprotein (with RRM2) and cell cycle (without RRM2), only in HCC terms of cell-cell signaling, cell projection part, glycoprotein, cell projection, cell adhesion, biological adhesion, integral to plasma membrane, plasma membrane, kinase and phosphorus metabolic process (without RRM2), and none in HCC terms of cell death (without RRM2) and ion binding (with RRM2) compared with human no-tumor hepatitis/cirrhotic liver tissues, all the condition is vital to invasion of HCC. Therefore, we deduced the weaker RRM2 phosphoprotein function in HCC consistent with our above computation. It would be necessary of RRM2 phosphoprotein function decrease to invasion of HCC. RRM2 phosphoprotein interaction module construction in HCC can be a new route for studying the pathogenesis of HCC.

Citing Articles

MicroRNA-582-3p targeting ribonucleotide reductase regulatory subunit M2 inhibits the tumorigenesis of hepatocellular carcinoma by regulating the Wnt/β-catenin signaling pathway.

Xu H, Li B Bioengineered. 2022; 13(5):12876-12887.

PMID: 35609318 PMC: 9275912. DOI: 10.1080/21655979.2022.2078026.


Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein.

Wang R, Xu Z, Tian J, Liu Q, Dong J, Guo L Am J Cancer Res. 2021; 11(6):2975-2989.

PMID: 34249439 PMC: 8263682.


Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.

Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J World J Surg Oncol. 2021; 19(1):66.

PMID: 33685467 PMC: 7938465. DOI: 10.1186/s12957-021-02174-w.


Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.

Gaspersic J, Videtic Paska A Biochem Med (Zagreb). 2020; 30(3):030504.

PMID: 32774122 PMC: 7394254. DOI: 10.11613/BM.2020.030504.


Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma.

Yue C, Ren Y, Ge H, Liang C, Xu Y, Li G Onco Targets Ther. 2019; 12:561-576.

PMID: 30679912 PMC: 6338110. DOI: 10.2147/OTT.S188913.